Blog

CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi (CCAD). Earlier this year, in May 2025, SKNJCT-004 received “study may proceed” approval from the UAE Department of Health.

The study is expected to randomize thirty-six (36) patients in four sites in UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD).

Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

“Commencing patient recruitment in the SKNJCT-004 clinical study at Cleveland Clinic Abu Dhabi is a promising step forward towards our goal to bring to market a first in class novel non-invasive alternative to treat BCC “, stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO “We have already randomized more than seventy five percent (75%) of the ninety (90) participants expected to be randomized in our AI powered SKNJCT-003 study, in the United States, which we believe represents more than US$2 billion in potential market opportunity”.

Clinical Trial Design (SKNJCT-004)

The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.

The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company’s Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.

The Company also has the SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to ninety (90) subjects and is expanding clinical trial sites in Europe. In August 2025, the Company announced that SKNJCT-003 has now randomized more than seventy five percent (75%) of the ninety (90) participants expected to be randomized in the study.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev Limited (“Antev”), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

For further information contact:

Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the potential benefits of the Antev transaction, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. . Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

INDIANAPOLIS, INDIANA / ACCESS Newswire / September 8, 2025 / Arrive AI (Nasdaq:ARAI) today announced that its Board of Directors has authorized a share repurchase program of up to $10 million of the Company’s common stock from now through March 31, 2026.

The authorization reflects the Board’s view that the current share price represents an attractive investment relative to Arrive AI’s long-term opportunities. Repurchases may be made from time to time in the open market, through privately negotiated transactions, or under Rule 10b5-1 trading plans, in each case in accordance with Rule 10b-18 under the Securities Exchange Act of 1934 and subject to market conditions and other factors, including customary blackout periods. The program may be modified, suspended, or terminated at any time at the Company’s discretion. The timing and actual number of shares repurchased, if any, will depend on a variety of factors, including price, liquidity, and alternative uses of capital.

Dan O’Toole, Founder and CEO of Arrive AI, said:
“We believe ARAI is materially undervalued given our momentum and the scale of the opportunity in autonomous, secure delivery. This authorization gives us the flexibility to be opportunistic when conditions are favorable, while we continue executing and building long-term shareholder value at the last inch of the last-mile.”

⸻

About Arrive AI

Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered Arrive Points™, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and via the company’s press kit.

⸻

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s share repurchase program, strategic priorities, and prospects. Forward-looking statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, among others, market conditions, the trading price and liquidity of the Company’s common stock, the Company’s financial performance, available capital, alternative uses of capital, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law. There is no assurance as to the timing, number, or value of shares to be repurchased under the program, if any, and the program may be modified, suspended, or discontinued at any time.

⸻

Media & Investor Contact
Kylie Conway
Arrive AI
investorrelations@arriveai.com | 463-270-0092

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

MIAMI, FLORIDA / ACCESS Newswire / September 8, 2025 / Safe & Green Holdings Corp. (NASDAQ:SGBX) (“Safe & Green” or the “Company”), a leading provider of modular solutions and sustainable infrastructure, today announced it has entered into an Open Collaborative Framework (“OCF”) with OneQode, a global technology company recognized for its high-performance networking and digital infrastructure capabilities.

The OCF is designed to create an open, ongoing collaboration between the parties. Initially, the partnership will focus on combining OneQode’s advanced technology capabilities with Safe & Green’s operational expertise to support infrastructure, automation, and production optimization. The framework also lays the foundation for future collaboration, including potential joint infrastructure projects, co-development of solutions for the energy sector and related industries, and other mutually beneficial commercial opportunities.

Key objectives under the OCF include:

• Exploring technology solutions to support in-field assets, software development, and operational optimization;

• Designing and piloting distributed command-and-control systems for field wells and micro-refinery nodes, including real-time pump control and spill-detection response;

• Evaluating connectivity solutions using enterprise LEO satellite, terrestrial links, and OneQode’s private routing to enable low-latency, resilient telemetry and command paths;

• Developing and preparing solutions for potential sale to third-party oil and gas operators.

While the OCF does not establish a joint venture or legal entity, both parties will contribute resources including personnel, technical expertise, marketing support, and infrastructure capabilities to advance collaborative projects. The agreement underscores a commitment to building long-term growth together through innovative technology applications in infrastructure and energy.

OCF representative clients include Citadel and Susquehanna.

Mike Mclaren, CEO of Safe & Green Holdings, commented, “This framework with OneQode marks an exciting step in our strategy to leverage innovative technology to enhance operational efficiency and infrastructure capabilities. By aligning OneQode’s networking and digital expertise with Safe & Green’s modular solutions, we are creating opportunities for meaningful, scalable solutions that support not only our business but also the broader energy sector.”

About Safe & Green Holdings Corp.
Safe & Green Holdings Corp. (NASDAQ:SGBX) is a leading provider of modular construction and sustainable infrastructure solutions, serving customers across multiple industries including healthcare, education, energy, and government. The Company’s subsidiaries focus on delivering innovative, cost-efficient, and environmentally conscious solutions that drive long-term value creation.

About OneQode
OneQode is a global infrastructure-as-a-service (IaaS) company delivering high-performance networking, compute, and digital infrastructure solutions. With expertise in low-latency routing, private networking, and distributed architectures, OneQode enables organizations to deploy secure, resilient, and scalable technology systems worldwide.

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Open Collaboration Framework between the Company and OneQode.. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully implement key objectives of the OCF, the Company’s ability to successfully combine OneQode’s advanced technology capabilities with the Company’s operational expertise to support infrastructure, automation, and production optimization, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Investors:

investors@safeandgreenholdings.com

SOURCE: Safe & Green Holdings Corp

View the original press release on ACCESS Newswire

OCONOMOWOC, WISCONSIN / ACCESS Newswire / September 8, 2025 / Solstice Health is proud to announce that we have been named to the 2025 Inc. 5000 list, debuting at No. 1520. Each year, Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, recognizes the fastest-growing private companies across America, and it is an incredible honor to be included among such an accomplished group of innovators and industry leaders. The list provides a data-driven snapshot of the most successful companies within the economy’s most dynamic segment-its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia.

“ The Inc. 5000 is a tremendous honor that reflects what our patients already know-this is the future of healthcare, and it’s happening right now in Wisconsin, ” said Dr. Timothy Murray, founder and CEO of Solstice Health. “ Our vision was never to simply improve healthcare, it was to rebuild it from the ground up. In the past three years, we’ve gone from two clinics to five, creating the nation’s only model that combines Direct Primary Care , Direct Surgical Care , and advanced treatments like Hyperbaric Oxygen Therapy under one roof. By offering transparent, bundled pricing that’s 70-80% lower than hospitals, we’ve shown that patients can have exceptional care without financial barriers or insurance interference. “

This year’s Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years.

For the full list, company profiles, and a searchable database by industry and location, visit: www.inc.com/inc5000 .

“Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company’s tenacity and clarity of vision,” says Mike Hofman, editor-in-chief of Inc. “These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn’t just weather the storm-they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.”

Inc. will celebrate the honorees at the 2025 Inc. 5000 Conference & Gala, taking place October 22-24 in Phoenix, and the top 500 will be listed in the Fall issue of Inc. magazine.

The Future of Healthcare, Built in Wisconsin

Founded in Wisconsin in 2012, Solstice Health is redefining what it means to deliver healthcare in America. Frustrated by the inefficiencies and depersonalization of the insurance-based “sick care” system, Timothy J. Murray, M.D. built Solstice Health on a membership driven Direct Primary Care (DPC) model, dramatically increasing patient accessibility and improving care with a proactive, prevention-focused approach for individuals and employers. This model also allows for additional savings via wholesale labs, imaging, and pharmaceuticals for all members.

With a broader vision for additional services and a true healthcare paradigm shift, Dr. Murray expanded Solstice Health to include a Multi-Specialty Ambulatory Surgery Center with a Cash Pay model offering transparent, bundled pricing at 70-80% less than the cost of any local hospital.

He has also recently developed their services to include medical-grade Hyperbaric Oxygen Therapy (HBOT) under one unified model to bypass the insurance and red tape barriers and provide patients with the care they deserve.

As Wisconsin’s premier, and the nation’s leading , non-insurance-based healthcare organization, Solstice Health is the only provider in the country to integrate DPC with Direct Surgical Care (DSC) offering advanced surgical services and many other ancillary services at prices that patients and employers can afford. With five clinics across Wisconsin and growing, Solstice Health delivers this new paradigm in healthcare, combining full scope Primary Care with Multi-Specialty Surgical excellence, cutting-edge HBOT, IV infusion therapy, medically supervised weight loss, and so much more. By creating a system where both providers and patients thrive, Dr. Murray has proven that healthcare transformation doesn’t have to be theoretical-it’s happening now. As a result, Solstice Health has been able to retain top-tier providers despite industry-wide staffing shortages and has made this a scalable model for sustainable healthcare innovation.

Methodology

Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent-not subsidiaries or divisions of other companies-as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.

About Inc.

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com .

About Solstice Health
Established in 2012, Solstice Health was founded by Timothy J. Murray, M.D., whose vision to offer affordable quality, transparent, and convenient medical care, has created a paradigm shift in health care delivery for Wisconsin. Over the past few years, Solstice Health has successfully expanded services to include Direct Primary Care, Direct Surgical Care, Hyperbaric Oxygen Therapy, Medically Supervised Weight Loss, IV Medication Infusions & Nutritional Therapy, and more. The company plans to continue its growth across Wisconsin, making this innovative model and cutting-edge therapies available to more communities and businesses.

Jessa Cisewski, RN & COO, SOLSTICE HEALTH, https://solsticewi.com, +1 262-354-3100, info@solsticewi.com

Facebook | Linkedin | Instagram | Twitter

SOURCE: Solstice Health

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / September 8, 2025 / Sewer Squad Plumbing & Drain Services has been named the 2025 Consumer Choice Award winner in the Drainage and Sewer Services category for the Greater Toronto Area. This recognition celebrates more than just technical expertise – it highlights Sewer Squad’s commitment to doing business differently: treating customers with respect, communicating openly, and delivering solutions without pressure or gimmicks.

Founded on the promise of straightforward service done right, Sewer Squad has built a reputation as a company homeowners can trust when the unexpected happens. The team is known for offering clear explanations, upfront pricing, and technicians who treat every home as if it were their own.

A People-First Approach

From its earliest days, Sewer Squad has believed that plumbing doesn’t have to be complicated, stressful, or intimidating. Instead of sales tactics or scare strategies, the focus has always been on education, transparency, and peace of mind.

“This award shows people see the way we do things. Our values guide us every day. We show up authentic, proactive, passionate and even bring some humour into the work. Homeowners trust that and it means a lot to be recognized for it.” – Phil Stinner, Owner

Recognition Rooted in Trust

The Consumer Choice Award is based on community feedback, making it a true reflection of how a business is perceived by the people it serves. For Sewer Squad, being recognized is proof that its values of honesty, reliability, and professionalism resonate with homeowners across the GTA.

“We are proud to be recognized by the Consumer Choice Award because it comes directly from the people we serve,” the Sewer Squad team adds. “For us, it’s more than a business achievement – it’s proof that taking care of people the right way still matters.”

Skilled Service Backed by Values

Sewer Squad offers a wide range of drainage and sewer solutions, from routine maintenance and emergency repairs to advanced diagnostics and sewer line replacements. But beyond the tools and technical skills, what sets the company apart is its culture: a commitment to respect, clear communication, and building long-term trust.

Built through Word-Of-Mouth

Rather than relying heavily on advertising, Sewer Squad has grown through referrals and repeat clients. Each service call is treated as an opportunity to build a lasting relationship – and that customer-driven growth has become the foundation of the company’s success.

Looking Ahead

With the 2025 Consumer Choice Award as a milestone, Sewer Squad remains focused on serving the Greater Toronto Area with integrity and care. For the team, this recognition isn’t just a business achievement – it’s motivation to keep proving that plumbing can be straightforward, honest, and people-centred.

“We want ‘call the Squad’ to be the first thing people think of when they need plumbing, and to grow into a trusted household name in the GTA and across Canada. We’ll keep proving it with honest, straightforward service every day.” – Phil Stinner, Owner

To learn more about Sewer Squad Plumbing & Drain Services or to book an appointment, visit www.sewersquad.ca.

About Sewer Squad Plumbing & Drain Services
Sewer Squad Plumbing & Drain Services is a customer-focused plumbing company serving the Greater Toronto Area. Specialising in drainage and sewer services, the company offers everything from routine maintenance to emergency repairs. With a philosophy built on honesty, respect, and professional workmanship, Sewer Squad has earned a reputation as a trusted name in plumbing. Learn more at www.sewersquad.ca.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognising and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

ST. JOHN’S, NL / ACCESS Newswire / September 8, 2025 / Serenity Nursing and Home Support Services Ltd. (Serenity Home Care) has been recognised with the 2025-26 Consumer Choice Award in the Home Healthcare Services category for the St. John’s region. This award reflects nearly three decades of dedication to providing compassionate, reliable care that allows clients to remain in the comfort of their own homes while receiving the support they need.

For 29 years, Serenity Home Care has been a trusted provider of licensed home care services in the St. John’s metro area. As a family-run agency, the organisation is deeply rooted in the community, offering personalised care that prioritises the dignity, safety, and well-being of every client. By helping individuals age in place, Serenity Home Care ensures that families can feel confident their loved ones are receiving high-quality support tailored to their needs.

Comprehensive Home Healthcare Services

Serenity Home Care provides a wide range of services designed to make daily living easier and safer. From personal care, meal preparation, and homemaking to medication reminders, respite care, and dementia support, the agency’s compassionate staff helps clients maintain independence and comfort. Additional services such as companionship and community access allow clients to stay socially engaged and connected.

The agency’s commitment to excellence has also been recognised nationally with the Primer Award from Accreditation Canada, a distinction that highlights the quality and safety standards upheld by its dedicated team.

A Commitment to Families and Community

“At Serenity Home Care, our mission has always been to deliver care that feels like family,” says the Serenity Home Care leadership team. “Winning the 2025-26 Consumer Choice Award is an incredible honour and a reflection of the trust our community has placed in us. We remain committed to supporting individuals and families in St. John’s with compassion, professionalism, and the highest standards of care.”

Recognition From the Community

The Consumer Choice Award is the only organisation in North America that recognises business excellence based entirely on the opinions of consumers. Through an independent research process, winners are determined by evaluating reputation, customer satisfaction, and overall excellence. Serenity Home Care’s recognition demonstrates the confidence that the St. John’s community places in their services.

To learn more about Serenity Nursing and Home Support Services Ltd. or to arrange care, visit www.serenityhomecare.net or CLICK HERE.

About Serenity Nursing and Home Support Services Ltd.
Founded 29 years ago, Serenity Nursing and Home Support Services Ltd. (Serenity Home Care) is a licensed home care agency serving the St. John’s metro area. Family-owned and operated, the agency provides a full range of services, including personal care, respite, dementia care, companionship, meal preparation, homemaking, and community access. With a commitment to safety, compassion, and client dignity, Serenity Home Care has become a trusted name in Newfoundland and Labrador home healthcare. Learn more at www.serenityhomecare.net.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognising and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / September 8, 2025 / Lyons Elite Luxury Matchmaking, one of North America’s most exclusive matchmaking firms, has been named the 2025 Consumer Choice Award recipient in the Dating Services category for Toronto Central. Founded by award-winning entrepreneur Emily Lyons, the agency is known for delivering a bespoke matchmaking experience designed for high-achieving, relationship-minded individuals.

Since 2014, Lyons Elite has set the gold standard in personalized, discreet matchmaking. Built by request from some of Emily Lyons’ most discerning clients, the agency offers a curated, high-touch approach that prioritizes values, compatibility, and lasting connection-far beyond the surface-level matches of traditional dating platforms.

A Vision Built on Precision and Discretion

Lyons Elite was created with one goal: to elevate the dating experience for those who refuse to settle. With an exclusive client roster that includes executives, entrepreneurs, creatives, and athletes, the agency offers a matchmaking experience that is deeply personal, highly selective, and profoundly intentional.

“Our clients don’t chase love-they delegate the search to us,” says the Lyons Elite team. “We conduct a refined, proactive search based on long-term compatibility, shared values, and the kind of chemistry you can’t quantify in an app.”

The agency only accepts a limited number of clients at a time, ensuring the integrity of its elite network and allowing matchmakers to offer their signature level of strategy, care, and discretion.

Founder & CEO Emily Lyons: A Matchmaker by Design

At the helm of Lyons Elite is Emily Lyons, a serial entrepreneur with a decade-long reputation for connecting extraordinary people. Widely featured in outlets such as Vogue, Forbes, and Cosmopolitan, Emily is also the founder of Femme Fatale Media and clean beauty brand True Glue.

Her instinctive ability to understand people-and align them with both opportunity and one another-has made her one of the most trusted names in luxury matchmaking.

“Creating meaningful relationships requires more than data. It takes emotional intelligence, intuition, and vision,” says Lyons. “Lyons Elite was built to deliver that level of intentionality to those who expect more from life and love.”

An Elevated, Five-Step Matchmaking Process

Lyons Elite clients go through a thoughtfully designed five-phase process that includes private consultations, curated profiles, a professional photoshoot, and intentional introductions supported by expert coaching. Matches are hand-selected-not algorithm-generated-ensuring each connection is grounded in real compatibility and long-term potential.

Whether serving clients in Toronto, across Canada, or internationally, the firm’s matchmakers work quietly behind the scenes to deliver exceptional results with absolute discretion.

Recognition Backed by Results

The 2025 Consumer Choice Award is based on independent research, consumer feedback, and brand reputation. For Lyons Elite, this recognition affirms its standing as a leader in modern matchmaking and a trusted partner in its clients’ most personal journeys.

“We are honoured to receive this award,” says the Lyons Elite team. “It reflects the care and integrity we bring to every match and the trust our clients place in us to help shape one of the most important parts of their lives.”

As digital dating continues to evolve, Lyons Elite remains committed to offering an intentional alternative-one rooted in strategy, humanity, and high standards. With a growing international network and continued focus on deep compatibility, the agency will continue to lead the way in modern relationship building.

To learn more about Lyons Elite or apply for private matchmaking services, visit www.lyonselite.com or CLICK HERE.

About Lyons Elite Luxury Matchmaking
Founded in 2014 by entrepreneur Emily Lyons, Lyons Elite is a boutique matchmaking agency offering discreet, highly personalized services for successful professionals. With a selective membership model, a dedicated team of expert matchmakers, and a values-driven approach, Lyons Elite has become one of the most respected luxury matchmaking firms in North America.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognizing and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Feasibility studies to begin shortly | Targeting operations by end of 2026

HIGHLIGHTS

• Challenger JORC (2012) Mineral Resources Estimate (MRE) grows to 313koz Au (10.6Mt @ 0.92 g/t), incl. 194koz Au (1.87Mt @ 3.23 g/t) in existing open pit and underground mines:

  • Challenger Main Open Pit: 70,000oz Au (0.65Mt @ 3.36 g/t Au);

  • Challenger West Open pit: 11,600oz Au (0.03Mt @ 10.7 g/t Au);

  • Challenger Underground (above 215mRL): 89,400oz Au (0.98Mt @ 2.84 g/t Au); and

  • Challenger Deeps (below 90mRL): 23,000oz Au (0.21Mt @ 3.50 g/t Au).

• Almost all MRE mineralisation located in, on, or adjacent to, existing serviceable open pit and underground development – opportunities for low-cost access and production

• Preliminary estimate for full reinstatement of 600ktpa Central Gawler Mill only A$26m (± 30%)

• Targeting lower-cost, de-risked two phase transition to operations, with initial high-grade tailings reprocessing (as Phase 1), followed by restart of fresh rock operations (as Phase 2)

• Technical programs moving directly to definitive Feasibility, targeting operations by end of 2026; conversations underway with financiers for low-dilution credit financing options

ADELAIDE, AUSTRALIA / ACCESS Newswire / September 7, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to announce an updated MRE for its South Australian Challenger Gold Project (Challenger). This follows detailed remodelling of gold mineralisation on or near existing development drives within the historical Challenger underground mine (below the 900mRL level). This mineralisation was temporarily removed from Barton’s recent 30 June 2025 Challenger MRE update, pending final remodelling and re-estimation.

Full details are contained in the complete announcement, which can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here.

Commenting on the Challenger JORC Resources update, Barton MD Alexander Scanlon said:

“With gold Resources of over 300,000oz now confirmed adjacent to the Central Gawler Mill, the pieces are now in place for the startup of an initial multi-year ‘Stage 1′ operation. This represents a significant opportunity for Barton to join a select few of its peers by transitioning to operations at a period of record high gold prices.

“Our fully permitted Central Gawler Mill also offers considerable leverage in successfully delivering this outcome, with a potentially shorter, lower-cost, and lower-risk pathway to operations and BGD’s re-rating to ‘producer’ status. A successful outcome could then generate revenues and cash flow to fund our planned regional growth.

“We are now moving directly to definitive Feasibility studies targeting a two phase, de-risked development and the start of initial ‘Stage 1′ operations by the end of 2026. Barton has a very exciting 18 months ahead as we navigate this next stage of our corporate evolution.”

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

*Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 8 September 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,186koz Au (40.2Mt @ 0.92 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire